Woman of the Week: KaliVir Immunotherapeutics’ Helena Chaye

The triple threat CEO — scientist, lawyer and biotech pro — thinks she’s discovered a key to curing a wide range of cancers.

By Taren Grom • Feb. 8, 2023

Roche, Chiesi and the FDA change major leadership roles as they strive for growth in 2023

From Roche’s new pharma chief to the departure of the FDA’s gene therapy head, these moves are bound to shake up the industry.

By Karissa Waddick • Feb. 6, 2023

Explore the Trendline➔

Commercialization, marketing and social media

As the pharma industry stares down a historic patent cliff, macroeconomic headwinds and challenging R&D costs for increasingly complex medicines, nailing the launch of new medicines has become increasingly critical. 

By PharmaVoice staff

Entact Bio’s CEO is leading the company out of stealth and into a new age of protein enhancement

Victoria Richon’s latest venture is in the burgeoning field of protein-enhancing drugs that could target a range of diseases.

By Kelly Bilodeau • Feb. 6, 2023

Execs at Pfizer, Novartis, Amgen and GSK tackle shifting priorities — reflecting the state of Big Pharma

A menagerie of earnings calls this week showed where the Big Pharma players stand in 2023.

By Michael Gibney • Feb. 2, 2023

Woman of the Week: Bayer’s Dr. Yesmean Wahdan

The VP of medical affairs and women’s health is focused on an audacious goal to meet the needs of 100 million women globally.

By Taren Grom • Feb. 1, 2023

This biotech CEO secured two billion-dollar Big Pharma deals during the pandemic

With the industry focused on cancer and COVID-19, Marc de Garidel made deals centered on cardio.

By Michael Gibney • Jan. 31, 2023

Gilead’s commercial chief on why 2023 will be a ‘coming out’ year

With a rapidly expanding oncology pipeline and a new approval in HIV, Johanna Mercier discusses Gilead’s quest to transform.

By Meagan Parrish • Jan. 26, 2023

Economic crisis? J&J execs say that won’t stop them from hitting $60B target

The pharma giant's CEO Joaquin Duato and CFO Joseph Wolk showed that they're optimistic about reaching lofty goals despite hard economic times.

By Michael Gibney • Jan. 25, 2023

Woman of the Week: Dr. Lauren Lazar

As Calcium’s medical director, Lazar is leveraging next-generation innovation to create strategic connections between science and marketing for healthcare brands.

By Taren Grom • Jan. 25, 2023

Woman of the Week: Genetika+’s Talia Cohen Solal

The CEO is aiming to build a “brain-in-a-dish” to treat all patients for better mental health outcomes.

By Taren Grom • Jan. 18, 2023

Biopharma M&A may get the push it needs in 2023, but with a face lift

A flurry of recent deals has reinforced forecasts that the long drought is over — circumstances have changed though, and M&A may not be the same.

By Michael Gibney • Jan. 12, 2023

C-suite changes at Biogen, Bluebird, Novavax give insight into 2023 business plans

A breakdown of the most buzzworthy executive changes so far in the new year and how they’re causing ripples in the life sciences industry.

By Karissa Waddick • Jan. 10, 2023

Chinook Therapeutics nears the finish line in kidney disease

A company focused on kidney disease, Chinook is growing into a commercial outfit as its lead candidate approaches the market.

By Michael Gibney • Jan. 10, 2023

The kindred nature of martial arts and drug development

How the IRLAB Therapeutics CEO is guiding the company in its development of potentially groundbreaking Parkinson’s disease treatments.

By Alexandra Pecci • Jan. 9, 2023

What’s top of mind for industry execs at JPM?

Leaders in the space reveal the topics that are top of mind as the year’s biggest healthcare conference kicks off next week.

By Taren Grom • Jan. 6, 2023

Woman of the Week: Cambrian BioPharma’s Juliette Han

The CFO and COO is advancing moonshot efforts to address aging-related diseases for the "healthspan" company and is helping emerging biotechs bring innovations out of academia.

By Taren Grom • Jan. 4, 2023

The 2023 PharmaVoice Crystal Ball: Peering into the future of life sciences

A preview of the top trends on the minds of industry and market leaders for the new year.

By Taren Grom • Jan. 3, 2023

Forks in the road lead one medical expert to a ‘game changing’ liver treatment

Durect’s chief medical officer altered his retirement plans to take a leading role at the company, which is developing a treatment for severe alcohol-associated hepatitis.

By Alexandra Pecci • Jan. 3, 2023

From chemistry to canvas: What the pharma world can learn from art

Art and science are often viewed as diametric opposites, but these industry insiders say their passion for painting blends into their pharma work. 

By Karissa Waddick • Dec. 22, 2022

WoW: What a year

A look back at some of the most inspirational quotes from the Women of the Week podcasts in 2022.

By Taren Grom • Dec. 20, 2022

Blood cancer cures aren’t here yet — but incremental combinations bring the field closer

A series of small successes showed promise for the future of blood cancer treatments, particularly in the arena of drug combinations.

By Michael Gibney • Dec. 19, 2022

How one of the world’s most prolific inventors is guiding a plan to tackle all disease

Steve Quake, science head at the Chan Zuckerberg Initiative, is leveraging personal experiences and a deep background in R&D to lead an ambitious 100-year plan.

By Alexandra Pecci • Dec. 15, 2022

Woman of the Week: Exelixis’ Dr. Vicki Goodman

With several blockbuster products under her belt, veteran oncologist and drug developer Dr. Vicki Goodman is looking to further evolve Exelixis’ pipeline to address hard-to-treat cancers.

By Taren Grom • Dec. 14, 2022

At the heart of hematology breakthroughs, a community of researchers and patients comes together

As new and advanced therapies are revealed at the annual meeting of the American Society of Hematology this week, the patients are always at the center.

By Michael Gibney • Dec. 13, 2022

The pharma giants making the biggest strides with global drug access

A recent report ranks the top 20 pharma companies by how well they’re boosting a critical component of health equity.

By Kelly Bilodeau • Dec. 12, 2022